Chemistry:4F-MDMB-BINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C19H26FN3O3 |
| Molar mass | 363.433 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4F-MDMB-BINACA (also known as MDMB-4F-BINACA,[1] 4F-MDMB-BUTINACA or 4F-ADB) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.[2] It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.[3][4] 4F-MDMB-BINACA is an agonist of the CB1 receptor (EC50 = 7.39 nM),[5] though it is unclear whether it is selective for this target.[6] In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II throughout the world.[7]
Related compounds
The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020.[8]
Legal Status
United Kingdom
It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016.
United States
4F-MDMB-BINACA is considered a Schedule I controlled substance as a positional isomer of the Schedule I compound 5F-AMB (5F-MMB-PINACA / 5F-AMB-PINACA). There has been charges brought against individuals for possession and distribution of 4F-MDMB-BINACA due to it being a positional isomer of 5F-AMB.[9]
The DEA has temporarily placed 4F-MDMB-BUTICA (the indole core analog of 4F-MDMB-BINACA) into Schedule I status starting on December 12th, 2023, for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12th, 2025.[10]
North Dakota has placed 4F-MDMB-BINACA into Schedule I on 04/27/2023.[11]
See also
- 5F-MDMB-PINACA
- 5F-MDMB-PICA
- 5F-MMB-PINACA
- 5F-MPP-PICA
- AB-FUBINACA
- MDMB-5'Br-BUTINACA
References
- ↑ Pulver, Benedikt; Fischmann, Svenja; Gallegos, Ana; Christie, Rachel (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis 15 (3): 255–276. doi:10.1002/dta.3403.
- ↑ "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework". Journal of Forensic Sciences 64 (5): 1451–1461. September 2019. doi:10.1111/1556-4029.14101. PMID 31260580.
- ↑ "Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA-parent compounds and metabolite identification in blood, urine and cerebrospinal fluid". Forensic Science, Medicine, and Pathology 18 (4): 393–402. December 2022. doi:10.1007/s12024-022-00492-3. PMID 35699867.
- ↑ "Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases". Archives of Toxicology 96 (10): 2755–2766. October 2022. doi:10.1007/s00204-022-03332-z. PMID 35788413.
- ↑ "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience 11 (24): 4434–4446. December 2020. doi:10.1021/acschemneuro.0c00644. PMID 33253529.
- ↑ "4F-MDMB-BINACA(4F-MDMB-BUTINACA)". https://www.deadiversion.usdoj.gov/drug_chem_info/4F-MDMB-BINACA.pdf.
- ↑ "News: December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling". https://www.unodc.org/LSS/Announcement/Details/021820a0-8746-42a4-9ee3-47ce50b30ca3.
- ↑ "Analytical data for 4F-MDMB-BICA.". Hungarian Institute for Forensic Sciences.. 28 May 2020. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-MDMB-BICA-ID-HIFS-020.pdf.
- ↑ https://www.justice.gov/media/1126421/dl?inline=
- ↑ "Schedules of Controlled Substances: Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I". 4 April 2023. https://www.federalregister.gov/documents/2023/04/04/2023-06893/schedules-of-controlled-substances-temporary-placement-of-mdmb-4en-pinaca-4f-mdmb-butica.
- ↑ "AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency.". Sixty-eighth Legislative Assembly of North Dakota in Regular Session. 3 January 2023. https://www.ndlegis.gov/prod/assembly/68-2023/regular/documents/23-8099-04000.pdf.
 |  |
